Serum aldosterone and the incidence of hypertension in nonhypertensive persons

New England Journal of Medicine

Volumn 351, Issue 1, 2004, Pages 33-41+111

  Vasan, Ramachandran S ^a,b   Evans, Jane C ^a,b   Larson, Martin G ^a,b   Wilson, Peter W F ^c   Meigs, James B ^d   Rifai, Nader ^e   Benjamin, Emelia J ^a,b   Levy, Daniel ^a,b,f  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; SODIUM;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CONFIDENCE INTERVAL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RISK ASSESSMENT; SODIUM EXCRETION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; BLOOD; ECHOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE; HISTOLOGY; HYPERALDOSTERONISM; LONGITUDINAL STUDY; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR; URINE;

ALDOSTERONE; BLOOD PRESSURE; FEMALE; HEART VENTRICLES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SODIUM;

EID: 3042731163     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa033263     Document Type: Article

References (43)

1. Stewart PM. Mineralocorticoid hypertension. Lancet 1999;353:1341-7.
2. Takeda Y, Miyamori I, Inaba S, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997;29:45-8.
3. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000;36:495-500.
4. Lifton RP. Molecular genetics of human blood pressure variation. Science 1996;272:676-80.
5. Ganguly A. Primary aldosteronism. N Engl J Med 1998;339:1828-34.
6. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000;14:311-5.
7. Kaplan NM. Cautions over the current epidemic of primary aldosteronism. Lancet 2001;357:953-4.
8. Lim PO, MacDonald TM. Step test in hypertension. QJM 2000;93:703-5.
9. Ganguly A. Prevalence of primary aldosteronism in unselected hypertensive populations: screening and definitive diagnosis. J Clin Endocrinol Metab 2001;86:4002-4.
10. Collins RD, Weinberger MH, Dowdy AJ, Nokes GW, Gonzales CM, Luetscher JA. Abnormally sustained aldosterone secretion during salt loading in patients with various forms of benign hypertension: relation to plasma renin activity. J Clin Invest 1970;49:1415-26.
11. Lim PO, Struthers AD, MacDonald TM. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? J Hypertens 2002;20:11-5.
12. Genest J, Nowaczynski W, Boucher R, Kuchel O, Rojo-Ortega JM. Aldosterone and renin in essential hypertension. Can Med Assoc J 1975;113:421-31.
13. Ljungman, S, Aurell M, Hartford M, Wikstrand J, Berglund G. Blood pressure in relation to the renin-angiotensin-aldosterone system. Acta Med Scand 1982;211:351-60.
14. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10.
15. Wisenbaugh PE, Garst JB, Hull C, Freedman RJ, Matthews DN, Hadady M. Renin, aldosterone, sodium and hypertension. Am J Med 1972;52:175-86.
16. Tolagen K. Aldosterone in primary hypertension relationship to plasma renin activity and urinary electrolytes and a comparison with normotensive subjects. Scand J Clin Lab Invest 1978;38:487-93.
17. Walker WG, Whelton PK, Saito H, Russell RP, Hermann J. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects. Hypertension 1979;1:287-91.
18. Harrap SB, Clark SA, Fraser R, Towrie A, Brown AJ, Lever AF. Effects of sodium intake and aldosterone on the renal pressure-natriuresis. Am J Physiol 1988;254:F697-F703.
19. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol 1979;110:281-90.
20. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46. [Erratum, Arch Intern Med 1998;158:573.]
21. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46. [Erratum, Arch Intern Med 1998;158:573.]
22. Ito T, Woo J, Haning R, Horton R. A radioimmunoassay for aldosterone in human peripheral plasma including a comparison of alternate techniques. J Clin Endocrinol Metab 1972;34:106-12.
23. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
24. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001;358:1682-6.
25. Walsh CR, Larson MG, Vasan RS, Levy D. Serum potassium is not associated with blood pressure tracking in the Framingham Heart Study. Am J Hypertens 2002;15:130-6.
26. Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: John Wiley, 1989.
27. Kannel WB, Wolf PA, Garrison RJ. The Framingham Heart Study, 30-year follow-up: an epidemiological investigation. Section 34. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements. Bethesda, Md.: National Heart, Lung, and Blood Institute, February 1987. (NIH publication no. 87-2703.)
28. Young MJ, Funder JW. Mineralocorticoids, salt, hypertension: effects on the heart. Steroids 1996;61:233-5.
29. Espeland MA, Kumanyika S, Wilson AC, et al. Statistical issues in analyzing 24-hour dietary recall and 24-hour urine collection data for sodium and potassium intakes. Am J Epidemiol 2001;153:996-1006.
30. Schunkert H, Hense HW, Muscholl M, et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997;77:24-31.
31. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension: the Framingham Heart Study. Circulation 1994;90:179-85.
32. SAS/STAT software: changes and enhancements, through release 6.11. Cary, N.C.: SAS Institute, 1996.
33. Harris P. Evolution and the cardiac patient. Cardiovasc Res 1983;17:437-5.
34. Funder JW. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J 2002;144:Suppl:S8-S11.
35. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension 2000;35:858-63.
36. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a "no-salt" culture. Circulation 1975;52:146-51.
37. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994;269:24316-20.
38. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002;970:89-100.
39. Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10:1326-34.
40. Gomez-Sanchez EP, Zhou M, Gomez-Sanchez CE. Mineralocorticoids, salt and high blood pressure. Steroids 1996;61:184-8.
41. Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem 2002;48:1919-23.
42. Abdelhamid S, Blomer R, Hommel G, et al. Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. Am J Hypertens 2003;16:522-30.
43. Gordon T, Sorlie P, Kannel WB. Problems in the assessment of blood pressure: the Framingham Study. Int J Epidemiol 1976; 5:327-34.